Pomerantz LLP Launches Investigation into SELLAS Life Sciences

The investigation centers on whether executives at the NASDAQ-listed biotech firm engaged in securities fraud or unlawful business practices. On August 28, 2026, reports surfaced indicating that the company’s phase 3 trial for Galinpepimut-S had reached its 80th patient death—a pre-specified trigger point that mandates the public release of trial results. Despite this milestone, the company did not disclose the findings, leading to a sharp market reaction that saw shares close at $13.21.

Pomerantz LLP, a firm specializing in securities class action litigation, is now soliciting contact from affected investors to evaluate potential claims. The firm, which maintains offices globally, is looking to determine if shareholders were misled by the company’s silence during a period of significant clinical development. Investors affected by the share price decline are encouraged to contact Danielle Peyton at the firm to participate in the ongoing inquiry.